Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RAD52 | P43351 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661349 | 0.88 | MAPT (0.57) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL1895566 | 0.82 | MAPT (0.66) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL6664876 | 0.80 | MAPT (0.62) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL4655713 | 0.79 | MAPT (0.54) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL26309234 | 0.79 | MAOA (0.52) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL14998302 | 0.77 | MAOA (0.50) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL6664912 | 0.74 | MAPT (0.58) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL2639024 | 0.74 | NSD2 (0.51) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL9365329 | 0.74 | TERT (0.48) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR | |
| SCHEMBL7144984 | 0.73 | MAPT (0.67) | MAPTSMN1; SMN2MAPK1L3MBTL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102924682-A | Preparation method of colorful polyurethane emulsion | Jiaxing hexin chemical industry co ltd | 2013-02-13 | — | — | CN | disclosed |
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1087935-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | MAPT 4879/4885SMN1; SMN2 4126/4885MAPK1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.